• Citer

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

par Risi, Emanuela;Biagioni, Chiara;Benelli, Matteo;Migliaccio, Ilenia;McCartney, Amelia;Bonechi, Martina;Guarducci, Cristina;Hilbers, Florentine FS;Di Cosimo, Serena;Huober, J.;Romagnoli, Dario;Boccalini, Giulia;Vitale, Stefania;Sotiriou, Christos ;Biganzoli, Laura ;Di Leo, A.;Malorni, Luca
Référence Therapeutic advances in medical oncology, 11
Publication Publié, 2019-01-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Auteur:	Risi, Emanuela; Biagioni, Chiara; Benelli, Matteo; Migliaccio, Ilenia; McCartney, Amelia; Bonechi, Martina; Guarducci, Cristina; Hilbers, Florentine FS; Di Cosimo, Serena; Huober, J.; Romagnoli, Dario; Boccalini, Giulia; Vitale, Stefania; Sotiriou, Christos; Biganzoli, Laura; Di Leo, A.; Malorni, Luca
Informations sur la publication:	Therapeutic advances in medical oncology, 11
Statut de publication:	Publié, 2019-01-01
Sujet CREF:	Cancérologie
	Sciences bio-médicales et agricoles
	Médecine pathologie humaine
Mots-clés:	gene expression profiling
	HER2+ breast cancer
	neoadjuvant chemotherapy
	predictive biomarker
	RB pathway
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1758-8340
	info:doi/10.1177/1758835919891608
	info:pii/10.1177_1758835919891608
	info:scp/85076627598
	info:pmid/31853266
	PMC6906346